Skip to content

Range-Finding and Pilot Study For: Extended Fragrance Ingredients Surveillance Study (EFISS) - Surveillance Study to Monitor the Frequency of Contact Allergy to a Defined Group of Fragrance Ingredients with a View to Providing Reliable Information on Trends

Range-Finding and Pilot Study For: Extended Fragrance Ingredients Surveillance Study (EFISS) - Surveillance Study to Monitor the Frequency of Contact Allergy to a Defined Group of Fragrance Ingredients with a View to Providing Reliable Information on Trends - Pilot study: Extended Fragrance Ingredients Surveillance Study (EFISS)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON49753
Enrollment
50
Registered
2020-11-25
Start date
2022-04-21
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic contact dermatitis contact eczema

Interventions

None listed

Sponsors

The International Fragrance Association (IFRA)
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adulthood (>=18 years); 4 weeks before the day of application of the patch test - Legal competence

Exclusion criteria

Exclusion criteria: - Patients who have had topical steroids applied to their back less than 7 days before the application of the patch test. - Active skin disease or skin anomalies on the back - Immunosuppressive medication (e.g. oral cortosteroïds, methotrexate, cyclosporine) during or in the previous 4 weeks of the study; - pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frame
The results of the epicutaneous patch tests for the different concentrations of the fragrance materials according to the guidelines of the International Contact Dermatitis Research Group (ICDRG)

Secondary

MeasureTime frame
• Gain familiarisation with the additional materials • Test quality procedures designed to address intra- and inter centre variations • Test the CRF (Case Report Form: See Annex VI) and its administration

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)